Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings

Core Insights - Myriad Genetics reported revenue of $209.8 million for the quarter ended December 2025, a decrease of 0.4% year-over-year, with an EPS of $0.04 compared to $0.03 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $207.59 million by 1.07%, while the EPS surprised positively by 350% against a consensus estimate of -$0.02 [1] Revenue Breakdown - Prenatal revenue was $44.9 million, below the two-analyst average estimate of $47.02 million, showing no year-over-year change [4] - Hereditary Cancer revenue reached $96.8 million, surpassing the average estimate of $94.87 million, reflecting a year-over-year increase of 2.7% [4] - Tumor Profiling revenue was reported at $31.5 million, exceeding the two-analyst average estimate of $28.59 million, with a year-over-year growth of 2.3% [4] Stock Performance - Myriad's shares have declined by 26.9% over the past month, contrasting with a 1.8% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]